Sean McClain, AbSci

Months af­ter strik­ing a deal with Sanofi, Ab­Sci nails its largest fundraise yet to sup­port its pro­tein print­ing tech

Months af­ter nail­ing down a $10.4 mil­lion Se­ries D and a part­ner­ship with French phar­ma gi­ant Sanofi, Ab­Sci is pulling in its largest fundraise yet — $65 mil­lion to ad­vance what it calls its pro­tein print­ing tech.

The Van­cou­ver, WA-based biotech is work­ing on a more ef­fi­cient way to man­u­fac­ture pro­teins — from full-length an­ti­bod­ies to in­sulin — us­ing E. coli. The com­pa­ny says it’s on a quest to make pro­tein pro­duc­tion “as sim­ple as DNA syn­the­sis,” al­low­ing for swift pro­duc­tion of dif­fi­cult-to-pro­duce bio­ther­a­peu­tics. It’s tag­ging the Se­ries E for ex­pan­sion of its pro­duc­tion ca­pac­i­ty, which in­cludes a new 60,000-square-foot fa­cil­i­ty in Van­cou­ver.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.